These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22474298)

  • 1. Amantadine: the journey from fighting flu to treating Parkinson disease.
    Hubsher G; Haider M; Okun MS
    Neurology; 2012 Apr; 78(14):1096-9. PubMed ID: 22474298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.
    Iwahashi J; Tsuji K; Ishibashi T; Kajiwara J; Imamura Y; Mori R; Hara K; Kashiwagi T; Ohtsu Y; Hamada N; Maeda H; Toyoda M; Toyoda T
    J Clin Microbiol; 2001 Apr; 39(4):1652-3. PubMed ID: 11283109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dropped head associated with amantadine in Parkinson disease.
    Kataoka H; Ueno S
    Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-influenza A viral drug--amantadine].
    Tokimatsu I; Nasu M
    Nihon Rinsho; 2000 Nov; 58(11):2288-92. PubMed ID: 11225319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible new mechanism for the antiparkinsonian effect of amantadine.
    Bennett VL; Juorio AV; Li XM
    J Psychiatry Neurosci; 1999 Jan; 24(1):52-3. PubMed ID: 9987209
    [No Abstract]   [Full Text] [Related]  

  • 8. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
    Wolf E; Seppi K; Katzenschlager R; Hochschorner G; Ransmayr G; Schwingenschuh P; Ott E; Kloiber I; Haubenberger D; Auff E; Poewe W
    Mov Disord; 2010 Jul; 25(10):1357-63. PubMed ID: 20198649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
    Kubo S; Iwatake A; Ebihara N; Murakami A; Hattori N
    Parkinsonism Relat Disord; 2008; 14(2):166-9. PubMed ID: 17509924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological gambling in Parkinson disease is reduced by amantadine.
    Thomas A; Bonanni L; Gambi F; Di Iorio A; Onofrj M
    Ann Neurol; 2010 Sep; 68(3):400-4. PubMed ID: 20687121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine induced reversible corneal edema.
    Deogaonkar M; Wilson K; Vitek J
    J Clin Neurosci; 2011 Feb; 18(2):298-9. PubMed ID: 21163653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
    Dzudza M; Dzudza D
    Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
    [No Abstract]   [Full Text] [Related]  

  • 14. Electroretinographic changes in patients with parkinsonism treated with various classes of antiparkinsonian drugs.
    Filipová M; Balík J; Filip V; Rodný J; Krejcová H
    Act Nerv Super (Praha); 1979 Oct; 21(3):136-8. PubMed ID: 517077
    [No Abstract]   [Full Text] [Related]  

  • 15. Is pathological gambling in Parkinson's disease reduced by amantadine?
    Lee JY; Kim HJ; Jeon BS
    Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
    [No Abstract]   [Full Text] [Related]  

  • 16. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
    Iizuka J; Fischer R
    Nervenarzt; 1986 Mar; 57(3):184-6. PubMed ID: 3515215
    [No Abstract]   [Full Text] [Related]  

  • 17. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between amantadine and the onset of dementia in Parkinson's disease.
    Inzelberg R; Bonuccelli U; Schechtman E; Miniowich A; Strugatsky R; Ceravolo R; Logi C; Rossi C; Klein C; Rabey JM
    Mov Disord; 2006 Sep; 21(9):1375-9. PubMed ID: 16705684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amantadine in Parkinson's disease: pro and contra.
    Greulich W; Fenger E
    J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Report on the therapeutic use of rimantadine and amantadine].
    Pérez Rodríguez AE; Expósito Rivas L; Rodríguez Leyva O; Goyenechea Hernández A
    Rev Cubana Med Trop; 1992; 44(2):145-8. PubMed ID: 9768207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.